PLSE· Health Care› Medical Instruments & Supplies

Pulse Biosciences, Inc

Stage 2 · Advancing · week 34

As of Oct 22, 2026, Pulse Biosciences is in Stage 2, the uptrend phase, now in week 34 (since Feb 20, 2026). It closed at $52.68, 4.6% below its 52-week high and above its 200-day average, which is rising.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. More about the company

$52.68

+2.67% today

$3.8B · Mid cap

Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 18 in Medical Instruments & Supplies · #1 of 272 in Health Care

Is PLSE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 22w

S2 15w

S2 35w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 6w → S4 5w → S1 2w → S2 12w → S3 13w → S2 22w → S3 4w → S2 15w → S3 4w → S4 7w → S1 3w → S4 11w → S1 6w → S2 3w → S3 2w → S4 10w → S1 1w → S2 35w current

Total tracked: 165 weeks across 19 stage runs.

PLSE among Medical Instruments & Supplies1st of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%

vs 52W High

-4.6%

$12.66 lo$55.20 hi

4.6% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 34

1w13w26w

Week 34, mature

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

74.5%

200 DMA: $30.18 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.80x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+1.3%

+74.3%

+117.2%

YTD

+293.4%

+191.4%

Scan Membership

Breakout Watch

Latest: 2024-12-04

8 appearances in last 60 days. First seen: 2019-03-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 34 · Vol 0.80x

2026-10-21S2

Wk 34 · Vol 0.52x

2026-10-20S2

Wk 34 · Vol 0.71x

2026-10-19S2

Wk 34 · Vol 0.62x

2026-10-16S2

Wk 34 · Vol 0.60x

2026-10-15S2

Wk 33 · Vol 0.78x

2026-10-14S2

Wk 33 · Vol 0.81x

2026-10-13S2

Wk 33 · Vol 0.85x

2026-10-12S2

Wk 33 · Vol 0.81x

2026-10-09S2

Wk 33 · Vol 0.68x

2026-10-08S2

Wk 32 · Vol 0.58x

2026-10-07S2

Wk 32 · Vol 0.74x

Moving averages & range

50 DMA

$50.22

200 DMA

$30.18

52W High

$55.20

52W Low

$12.66

5D Low

$44.43

Resistance levels (recent highs)

20d High

$53.81

60d High

$55.20

120d High

$55.20

250d High

$55.20

Next resistance

+2.1%

to 20d High

ROE

-78.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 37.5

Pulse Biosciences: quick answers

What stage is Pulse Biosciences in?

As of Oct 22, 2026, Pulse Biosciences (PLSE) is in Stage 2, the uptrend phase. It entered Stage 2 on Feb 20, 2026 and is in week 34. What the four stages mean

Is Pulse Biosciences in an uptrend?

Yes. Pulse Biosciences is in a Stage 2 uptrend. It trades 74.5% above its 200-day average, which is rising.

How far is Pulse Biosciences from its 52-week high?

Pulse Biosciences closed at $52.68 on Oct 22, 2026, 4.6% below its 52-week high of $55.20. Its 52-week low is $12.66.

How has Pulse Biosciences performed over the past year?

As of Oct 22, 2026, Pulse Biosciences is up 191.4% over the past year and up 293.4% so far in 2026.

Which sector and industry is Pulse Biosciences in?

Pulse Biosciences is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.